Abstract
Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have